Skip to main content
    E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.63
    -0.33 (-4.74%)

    Market Cap: $460.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Evolus Inc (EOLS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Evolus reported revenue of $297.18M for the fiscal year ended Dec 31, 2025, up 11.6% from the year before. That year, net income was -$51.64M with a net margin of -17.4%, operating cash flow was -$42.27M and free cash flow was -$50.72M. The quarter ended Sep 30, 2026 had revenue of $77.95M and net income of -$12.52M.

    Revenue and Margins

    The operating margin was -11.0% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $34.92M, a compound annual rate of 42.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$297.18M+11.6%66.3%-11.0%-17.4%
    Dec 2024$266.27M+31.8%68.5%-12.9%-18.9%
    Dec 2023$202.09M+36.0%68.1%-24.4%-30.5%
    Dec 2022$148.62M+49.1%60.4%-44.0%-50.1%
    Dec 2021$99.67M+76.3%56.3%-44.6%-47.0%
    Dec 2020$56.54M+61.9%67.6%-270.7%-288.3%
    Dec 2019$34.92MN/A77.1%-283.3%-257.8%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$297.18M$266.27M$202.09M$148.62M$99.67M$56.54M$34.92M$0$0$0
    Cost of revenue$100.07M$83.97M$64.51M$58.84M$43.53M$18.30M$8.01M$0$0$326.00K
    Gross profit$197.11M$182.30M$137.57M$89.77M$56.14M$38.24M$26.91M$0$0-$326.00K
    Research and development$9.58M$9.17M$15.43M$6.74M$2.06M$1.72M$3.97M$6.49M$6.69M$12.61M
    Operating income-$32.66M-$34.41M-$49.23M-$65.33M-$44.41M-$153.07M-$98.95M-$46.14M-$11.73M-$19.97M
    Net income-$51.64M-$50.42M-$61.69M-$74.41M-$46.81M-$163.01M-$90.03M-$46.87M-$4.48M-$20.07M
    EBITDA-$23.17M-$27.12M-$41.55M-$59.76M-$36.88MN/AN/A-$46.13M-$11.51M-$19.64M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$77.95M$84.08M$73.14M$90.30M$68.97M$69.39M$68.52M$78.95M$61.09M$66.91M$59.33M$61.00M
    Gross profit$50.69M$57.18M$48.90M$59.29M$45.84M$45.32M$46.66M$52.63M$42.10M$47.07M$40.50M$38.77M
    Operating income-$8.43M-$4.54M-$6.85M$4.22M-$11.50M-$10.21M-$15.17M-$2.31M-$15.47M-$7.70M-$8.92M-$8.63M
    Net income-$12.52M-$8.05M-$10.67M$130.00K-$15.74M-$17.14M-$18.89M-$6.79M-$19.17M-$11.35M-$13.11M-$11.83M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $148.63M exceeded cash and equivalents by $94.80M. Shareholder equity was negative, at -$23.11M, as total liabilities of $248.97M exceeded total assets of $225.87M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$225.87M$232.57M$189.00M$177.98M$257.48M$209.07M$240.44M$171.84M$152.23M$77.50M
    Current assets$142.92M$151.34M$112.42M$100.80M$178.80M$127.61M$152.20M$94.34M$72.82M$211.00K
    Cash and equivalents$53.83M$86.95M$62.84M$53.92M$146.26M$102.56M$109.89M$93.16M$0$187.00K
    Total liabilities$248.97M$227.05M$209.69M$159.48M$175.61M$282.03M$160.99M$87.46M$227.78M$84.60M
    Short-term debt$2.53M$1.72M$1.38M$1.32M$1.26M$93.45M$0N/A$138.69M$59.76M
    Long-term debt$146.10M$121.51M$120.36M$71.88M$71.22M$40.51M$91.45M$16.90M$0N/A
    Shareholder equity-$23.11M$5.52M-$20.69M$18.50M$81.88M-$72.96M$79.46M$84.38M-$75.54M-$7.11M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$283.82M$248.02M$220.65M$225.87M$219.00M$228.80M$213.36M$232.57M$229.61M$233.77M$226.18M$189.00M
    Total liabilities$321.64M$278.93M$249.43M$248.97M$247.76M$247.46M$219.97M$227.05M$223.72M$214.46M$207.73M$209.69M
    Cash and equivalents$41.70M$45.17M$49.79M$53.83M$43.52M$61.74M$67.89M$86.95M$85.03M$93.67M$96.96M$62.84M
    Shareholder equity-$37.81M-$30.90M-$28.78M-$23.11M-$28.76M-$18.65M-$6.60M$5.52M$5.89M$19.31M$18.44M-$20.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$42.27M-$18.00M-$34.01M-$84.91M-$33.39M-$57.87M-$93.38M-$25.67M-$13.22M-$13.27M
    Capital expenditures$8.45M$4.82M$1.63M$2.94M$970.00K$3.14M$4.57M$9.00K$0$9.00K
    Free cash flow-$50.72M-$22.82M-$35.63M-$87.85M-$34.36M-$61.01M-$97.95M-$25.68M-$13.22M-$13.28M
    Share repurchases$0$248.00K$0$0$214.00K$0$203.00K$1.30M$1.29MN/A
    Investing cash flow-$8.45M-$4.82M-$1.63M-$2.94M$4.03M$12.19M-$23.43M-$9.00K$0-$9.00K
    Financing cash flow$17.34M$47.41M$44.64M-$4.15M$73.05M$38.35M$133.55M$118.84M$13.04M$13.27M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.93M-$3.59M-$9.95M$12.83M-$14.67M-$24.79M-$15.63M$4.81M-$5.72M-$6.47M-$10.62M$813.00K
    Capital expenditures$1.23M$500.00K$1.69M$2.17M$2.16M$2.27M$1.86M$1.36M$1.41M$1.25M$797.00K$361.00K
    Free cash flow-$3.17M-$4.09M-$11.64M$10.66M-$16.83M-$27.06M-$17.49M$3.45M-$7.13M-$7.72M-$11.41M$452.00K
    Last 12 quarters

    Frequently Asked Questions About EOLS

    What is Evolus' annual revenue?

    Evolus reported revenue of $297.18M for the fiscal year ended Dec 31, 2025.

    How fast is Evolus' revenue growing?

    Revenue was up 11.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 26.0%.

    Is Evolus profitable?

    No. Evolus reported net income of -$51.64M for the fiscal year ended Dec 31, 2025, with a net margin of -17.4%.

    How much free cash flow does EOLS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$42.27M minus capital expenditures of $8.45M produced free cash flow of -$50.72M.

    How much debt does Evolus have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $146.10M, short-term debt of $2.53M and cash and equivalents of $53.83M.